SGLT2 INHIBITORS: EFFECTS ON CARDIOPROTECTION - Boukheloua, Mourad;CHELGHOUM, SOUAD;GACEM, OURIDA
45,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
23 °P sammeln
  • Broschiertes Buch

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially developed as anti-hyperglycemic drugs, have been shown to significantly improve metabolic indicators and protect the kidneys and hearts of patients with and without type 2 diabetes. The possible mechanisms for these benefits are the subject of extensive research, as they cannot be attributed solely to improved blood sugar control. In this book, we will focus on the current understanding of cardio-renal protection by SGLT2 inhibitors by explaining the pathophysiological mechanisms involved, and we will present the largest trials that have demonstrated this organoprotective effect.…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially developed as anti-hyperglycemic drugs, have been shown to significantly improve metabolic indicators and protect the kidneys and hearts of patients with and without type 2 diabetes. The possible mechanisms for these benefits are the subject of extensive research, as they cannot be attributed solely to improved blood sugar control. In this book, we will focus on the current understanding of cardio-renal protection by SGLT2 inhibitors by explaining the pathophysiological mechanisms involved, and we will present the largest trials that have demonstrated this organoprotective effect.
Autorenporträt
Mourad BOUKHELOUA, Interventional cardiologist and Professor at the Faculty of Medicine in Algiers, Head of Interventional Cardiology at Hussein Dey University Hospital.Mohamed BERREHAL, Assistant Professor and Head of Interventional Cardiology at Sétif University Hospital.Toufik IAICHE ACHOUR, Professor, Head of Department of Anesthesia and Intensive Care, Hussein Dey University Hospital.